中国药物经济学
中國藥物經濟學
중국약물경제학
CHINA JOURNAL OF PHARMACEUTICAL ECONOMICS
2013年
4期
16-18
,共3页
抑郁障碍%抗抑郁药%药物经济学%成本-效果分析
抑鬱障礙%抗抑鬱藥%藥物經濟學%成本-效果分析
억욱장애%항억욱약%약물경제학%성본-효과분석
Depressive disorder%Antidepressant%Pharmacoeconomic%Cost-effectiveness analysis
目的对常用的抗抑郁药物艾司西酞普兰与文拉法辛治疗抑郁障碍进行成本-效果分析。方法将78例符合《中国精神障碍分类与诊断标准》(第三版)抑郁发作诊断标准的抑郁障碍患者随机分为两组,分别给予艾司西酞普兰或文拉法辛治疗8周,观察两组治疗方案的疗效及安全性,运用药物经济学的成本-效果分析方法进行评价。结果艾司西酞普兰、文拉法辛组治疗药品成本分别为663.04元和1164.80元;有效率分别为82.05%和84.62%;不良反应发生率分别为30.77%和28.21%。结论根据药物经济学评价,艾司西酞普兰组优于文拉法辛组。
目的對常用的抗抑鬱藥物艾司西酞普蘭與文拉法辛治療抑鬱障礙進行成本-效果分析。方法將78例符閤《中國精神障礙分類與診斷標準》(第三版)抑鬱髮作診斷標準的抑鬱障礙患者隨機分為兩組,分彆給予艾司西酞普蘭或文拉法辛治療8週,觀察兩組治療方案的療效及安全性,運用藥物經濟學的成本-效果分析方法進行評價。結果艾司西酞普蘭、文拉法辛組治療藥品成本分彆為663.04元和1164.80元;有效率分彆為82.05%和84.62%;不良反應髮生率分彆為30.77%和28.21%。結論根據藥物經濟學評價,艾司西酞普蘭組優于文拉法辛組。
목적대상용적항억욱약물애사서태보란여문랍법신치료억욱장애진행성본-효과분석。방법장78례부합《중국정신장애분류여진단표준》(제삼판)억욱발작진단표준적억욱장애환자수궤분위량조,분별급여애사서태보란혹문랍법신치료8주,관찰량조치료방안적료효급안전성,운용약물경제학적성본-효과분석방법진행평개。결과애사서태보란、문랍법신조치료약품성본분별위663.04원화1164.80원;유효솔분별위82.05%화84.62%;불량반응발생솔분별위30.77%화28.21%。결론근거약물경제학평개,애사서태보란조우우문랍법신조。
Objective To commonly used antidepressant escitalopram and Vin Rafa Sin in the treatment of depression for cost-effectiveness analysis. Methods 78 patients with"Chinese classification and diagnostic criteria of mental disorders (Third Edition)"in patients with depressive disorder were randomly divided into depression diagnosis standard into two groups,were treated with escitalopram and venlafaxine in the treatment of 8 weeks, to observe the safety and efficacy of treatment group two, using the pharmacoeconomic cost-effectiveness analysis. Result Escitalopram, venlafaxine group therapy drug costs were 663.04 yuan and 1164.80 yuan; the effective rates were 82.05%and 84.62%;the incidence of adverse reaction was 30.77%and 28.21%respectively. Conclusion On the basis of pharmacoeconomic evaluation, escitalopram group was better than that of venlafaxine group.